drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Humanized anti-CD19 IgG1 monoclonal antibody (IV) that depletes CD19+ B cells and plasmablasts via ADCC/CDC to reduce pathogenic AQP4-IgG autoantibodies in NMOSD.
nci_thesaurus_concept_id
C88283
nci_thesaurus_preferred_term
Inebilizumab
nci_thesaurus_definition
A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
drug_mesh_term
Inebilizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized, afucosylated anti-CD19 IgG1 monoclonal antibody that binds CD19 on B-lineage cells (including plasmablasts) and depletes them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, reducing production of pathogenic AQP4-IgG autoantibodies in NMOSD.
drug_name
Inebilizumab
nct_id_drug_ref
NCT05549258